Rapid and sustained response of stubborn guttate psoriasis to ustekinumab: A 52-week, two-center, one-arm, observational study
收藏NIAID Data Ecosystem2026-05-02 收录
官方服务：
资源简介：
Demographic and baseline disease characteristics of Chinese GP patients
应用场景：
创建时间：
2024-11-28
相关数据集
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight
NIAID Data Ecosystem40
Background of five patients and five healthy controls.
The PASI score of the patients was high before ustekinumab therapy, and improved dramatically after the treatment. However, the PASI score of case 5 was increased at one month after the third therapy.
Figshare2015-12-02 更新20
Supplementary Material for: Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival
Psoriasis is a complex and chronic disease, and, in most cases, therapies are required during all patients’ lifetime. The efficacy and safety profiles of biological therapies are well established, but
Figshare2018-05-15 更新10
An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis
To undertake a comparison of Cal/BDP cream versus foam for the treatment of plaque psoriasis, with cross-trial population differences accounted for. An anchored matching-adjusted indirect comparison w
Taylor & Francis Group2024-05-16 更新30
Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial
Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial
NIAID Data Ecosystem10
